Pansini F, Bianchi A, Zito V, et al. Blood prolactin levels: inﬂuence of age, menstrual cycle and oral contraceptives. Contraception 1983;28:201–207.
260.
Pansini F, Bergamini CM, Cavallini AR, et al. Prolactinemia during the menstrual cycle. A possible role for prolactin in the regulation of ovarian function. Gynecol Obstet Invest 1987;23:172–176.
261.
Bohnet HG, Dahlen HG, Wuttke W, et al. Hyperprolactinemic anovulatory syndrome. J Clin Endocrinol Metab 1976;42:132– 143.
262.
Franks S, Murray MA, Jequier AM, et al. Incidence and significance of hyperprolactinaemia in women with amenorrhea. Clin Endocrinol (Oxf) 1975;4:597–607.
263.
Jacobs HS, Hull MG, Murray MA, et al. Therapy-orientated diagnosis of secondary amenorrhoea. Horm Res 1975;6:268–287.
264.
Boyar RM, Kapen S, Finkelstein JW, et al. Hypothalamic-pituitary function in diverse hyperprolactinemic states. J Clin Invest 1974;53:1588–1598.
265.
Moult PJ, Rees LH, Besser GM. Pulsatile gonadotrophin secretion in hyperprolactinaemic amenorrhoea an the response to bromocriptine therapy. Clin Endocrinol (Oxf) 1982;16:153–162.
266.
Buckman MT, Peake GT, Srivastava L. Patterns of spontaneous LH release in normo-and hyperprolactinaemic women. Acta Endocrinol (Copenh) 1981;97:305–310.
267.
Aono T, Miyake A, Yasuda TS, et al. Restoration of oestrogen positive feedback effect on LH release by bromocriptine in hyperprolacti 291.
Weiss MH, Wycoff RR, Yadley R, et al. Bromocriptine treatment of prolactin-secreting tumors: surgical implications. Neurosurgery 1983;12:640–642.
292.
Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas. Cancer 2004;101:613–619.
293.
Klibanski A, Biller BM, Rosenthal DI, et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988;67:124–130.
294.
Turner TH, Cookson JC, Wass JA, et al. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J (Clin Res Ed) 1984;289:1101–1103.
295.
Katz E, Weiss BE, Hassell A, et al. Increased circulating levels of bromocriptine after vaginal compared with oral administration. Fertil Steril 1991;55:882–884.
296.
Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29–38.
297.